Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Omeros Corporation < Previous 1 2 Next > FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy October 24, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Second Quarter 2024 Financial Results August 07, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 August 05, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Announces Webcast Details for Annual Meeting of Shareholders June 04, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 June 03, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports First Quarter 2024 Financial Results May 15, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 May 10, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress May 09, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results April 01, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 March 27, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy February 20, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust February 01, 2024 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Third Quarter 2023 Financial Results November 09, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 November 06, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy November 03, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting November 02, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer October 19, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy October 16, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Second Quarter 2023 Financial Results August 09, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023 August 04, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Announces Webcast Details for Annual Meeting of Shareholders June 21, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress June 12, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress June 01, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports First Quarter 2023 Financial Results May 09, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023 May 04, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria April 25, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program April 10, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results March 13, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank March 10, 2023 From Omeros Corporation Via Business Wire Tickers OMER Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023 March 07, 2023 From Omeros Corporation Via Business Wire Tickers OMER < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
